329 related articles for article (PubMed ID: 34681910)
1. Myelodysplastic Syndromes and Metabolism.
Balaian E; Wobus M; Bornhäuser M; Chavakis T; Sockel K
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681910
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow niche in the myelodysplastic syndromes.
Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?
Pleyer L; Valent P; Greil R
Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27355944
[TBL] [Abstract][Full Text] [Related]
4. The microenvironment in myelodysplastic syndromes: Niche-mediated disease initiation and progression.
Li AJ; Calvi LM
Exp Hematol; 2017 Nov; 55():3-18. PubMed ID: 28826860
[TBL] [Abstract][Full Text] [Related]
5. Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes.
Abbas S; Kini A; Srivastava VM; M MT; Nair SC; Abraham A; Mathews V; George B; Kumar S; Venkatraman A; Srivastava A
Blood Cells Mol Dis; 2017 Jul; 66():37-46. PubMed ID: 28822917
[TBL] [Abstract][Full Text] [Related]
6. Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis.
Wenk C; Garz AK; Grath S; Huberle C; Witham D; Weickert M; Malinverni R; Niggemeyer J; Kyncl M; Hecker J; Pagel C; Mulholland CB; Müller-Thomas C; Leonhardt H; Bassermann F; Oostendorp RAJ; Metzeler KH; Buschbeck M; Götze KS
Blood Adv; 2018 Dec; 2(23):3447-3461. PubMed ID: 30518537
[TBL] [Abstract][Full Text] [Related]
7. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
[TBL] [Abstract][Full Text] [Related]
8. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression.
Weickert MT; Hecker JS; Buck MC; Schreck C; Rivière J; Schiemann M; Schallmoser K; Bassermann F; Strunk D; Oostendorp RAJ; Götze KS
Sci Rep; 2021 Mar; 11(1):5944. PubMed ID: 33723276
[TBL] [Abstract][Full Text] [Related]
10. What is the role of the microenvironment in MDS?
Calvi LM; Li AJ; Becker MW
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101113. PubMed ID: 31779976
[TBL] [Abstract][Full Text] [Related]
11. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
12. Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications.
Mies A; Bulycheva E; Rogulj IM; Hofbauer LC; Platzbecker U
Curr Pharm Des; 2016; 22(16):2323-32. PubMed ID: 26916019
[TBL] [Abstract][Full Text] [Related]
13. Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.
Balaian E; Weidner H; Wobus M; Baschant U; Jacobi A; Mies A; Bornhäuser M; Guck J; Hofbauer LC; Rauner M; Platzbecker U
Ann Hematol; 2019 Sep; 98(9):2063-2072. PubMed ID: 31312928
[TBL] [Abstract][Full Text] [Related]
14. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
[TBL] [Abstract][Full Text] [Related]
15. [Senescent Mesenchymal Stem Cells Contribute to Progression of Myelodysplastic Syndromes-Review].
Pang YB; Li WW; Luo JM; Ji J; DU X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):942-946. PubMed ID: 29950248
[TBL] [Abstract][Full Text] [Related]
16. Biologic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes.
Kastrinaki MC; Pontikoglou C; Klaus M; Stavroulaki E; Pavlaki K; Papadaki HA
Curr Stem Cell Res Ther; 2011 Jun; 6(2):122-30. PubMed ID: 20528751
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy.
Poon Z; Dighe N; Venkatesan SS; Cheung AMS; Fan X; Bari S; Hota M; Ghosh S; Hwang WYK
Leukemia; 2019 Jun; 33(6):1487-1500. PubMed ID: 30575819
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH.
Oliveira FM; Lucena-Araujo AR; Favarin Mdo C; Palma PV; Rego EM; Falcão RP; Covas DT; Fontes AM
Exp Hematol; 2013 Feb; 41(2):198-208. PubMed ID: 23092930
[TBL] [Abstract][Full Text] [Related]
19. Aging- and Senescence-associated Changes of Mesenchymal Stromal Cells in Myelodysplastic Syndromes.
Mattiucci D; Maurizi G; Leoni P; Poloni A
Cell Transplant; 2018 May; 27(5):754-764. PubMed ID: 29682980
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal Stem Cells in Aplastic Anemia and Myelodysplastic Syndromes: The "Seed and Soil" Crosstalk.
Fattizzo B; Giannotta JA; Barcellini W
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
